Treatment with Cerebrolysin Prolongs Lifespan in a Mouse Model of Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy.

Kastberger B, Winter S, Brandstätter H, Biller J, Wagner W, Plesnila N

Advanced biology7 Dec 2023Cited by 4 (Europe PMC)

PMID38062874DOI10.1002/adbi.202300439PepBankPUB-38062874

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In CADASIL model mice, Cerebrolysin improved spatial memory compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin improved spatial memory compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseSpatial memory
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
Cerebrolysin treatment improves spatial memory and overall health, reduces epigenetic aging, and prolongs lifespan, however, CADASIL-specific white matter vacuolization is not affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287401
02AnimalAnimal study (in vivo)Efficacy outcome
In CADASIL model mice, Cerebrolysin improved overall health compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin improved overall health compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseOverall health
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Aging markers · Whole body
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
Cerebrolysin treatment improves spatial memory and overall health, reduces epigenetic aging, and prolongs lifespan, however, CADASIL-specific white matter vacuolization is not affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287402
03AnimalAnimal study (in vivo)Efficacy outcome
In CADASIL model mice, Cerebrolysin reduced epigenetic aging compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin reduced epigenetic aging compared with vehicle.
Peptide
Cerebrolysin
Outcome
DecreaseEpigenetic aging
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Aging markers · Aging and longevity
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
Cerebrolysin treatment improves spatial memory and overall health, reduces epigenetic aging, and prolongs lifespan, however, CADASIL-specific white matter vacuolization is not affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287403
04AnimalAnimal study (in vivo)Efficacy outcome
In CADASIL model mice, Cerebrolysin prolonged lifespan compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin prolonged lifespan compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseLifespan
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Mortality · Aging and longevity
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
Cerebrolysin treatment improves spatial memory and overall health, reduces epigenetic aging, and prolongs lifespan, however, CADASIL-specific white matter vacuolization is not affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287404
05AnimalAnimal study (in vivo)Efficacy outcome
In CADASIL model mice, Cerebrolysin did not affect CADASIL-specific white matter vacuolization compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin did not affect disease-specific white matter vacuolization compared with vehicle.
Peptide
Cerebrolysin
Outcome
No significant changeWhite matter vacuolization
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
Cerebrolysin treatment improves spatial memory and overall health, reduces epigenetic aging, and prolongs lifespan, however, CADASIL-specific white matter vacuolization is not affected.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287405
06AnimalAnimal study (in vivo)Mechanism
In CADASIL model mice, Cerebrolysin increased CGRP expression compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin increased CGRP expression compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseCGRP expression
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
On the molecular level Cerebrolysin treatment increases expression of Calcitonin Gene-Related Peptide (CGRP) and Silent Information Regulator Two (Sir2)-like protein 6 (SIRT6)
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287406
07AnimalAnimal study (in vivo)Mechanism
In CADASIL model mice, Cerebrolysin increased SIRT6 expression compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin increased SIRT6 expression compared with vehicle.
Peptide
Cerebrolysin
Outcome
IncreaseSIRT6 expression
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
On the molecular level Cerebrolysin treatment increases expression of Calcitonin Gene-Related Peptide (CGRP) and Silent Information Regulator Two (Sir2)-like protein 6 (SIRT6)
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287407
08AnimalAnimal study (in vivo)Mechanism
In CADASIL model mice, Cerebrolysin decreased IGF-1 expression compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin decreased IGF-1 expression compared with vehicle.
Peptide
Cerebrolysin
Outcome
DecreaseIGF-1 expression
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
decreases expression of Insulin-like Growth Factor 1 (IGF-1), and normalizes the expression of neurovascular laminin.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287408
09AnimalAnimal study (in vivo)Mechanism
In CADASIL model mice, Cerebrolysin normalized neurovascular laminin expression compared with vehicle.
In plain wordsIn mice with CADASIL, Cerebrolysin normalized neurovascular laminin expression compared with vehicle.
Peptide
Cerebrolysin
Outcome
Not applicableNeurovascular laminin expression
Study
mousen = 176
NOTCH3 R169C mutant CADASIL mice
Comparator
Vehicle
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated · nine weeksAs given in this study (mouse).
Source sentences
Summary
decreases expression of Insulin-like Growth Factor 1 (IGF-1), and normalizes the expression of neurovascular laminin.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve-month-old NOTCH3^R169C mutant mice (n=176) are treated for nine weeks with Cerebrolysin or Vehicle and histopathological and functional outcomes are evaluated within the subsequent ten months.
Report a problemFND-3806287409

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.